Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time. AbbVie's fundamentals ...

It's in Novo Nordisk's best interest to produce more winning ... which acts as a drug delivery system, with the plan being for ambient cellular machinery within the patient's body to handle ...

Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the pharmaceutical giant's third quarter results could show a slowing in sales of ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients. The Danish pharmaceutical giant said late Thursday ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...

Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works — but according to its trial results, it has some pretty grim side effects. As Fierce Biotech ...

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs as skeptical senators criticized the Danish ...

Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving mixed data on its new oral weight-loss pill — the cannabinoid receptor Monlunabant — and is ramping up the ...

Senators grilled the top executive of Novo Nordisk over why the Danish company ... by the vast majority of private health insurance plans, as well as Medicare and Medicaid, the government health ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a ...